Contact | Print version | PDF version | Send article | RSS feed

Crucell and NIH sign EUR 21.4 million Ebola Vaccine Manufacturing Contract

15 Apr 2005 - Crucell N.V. announced that it has signed a manufacturing contract with the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), for the manufacture of vaccines against Ebola infections. Under the terms of the contract, Crucell will manufacture up to ten batches of clinical material of the PER.C6®-based Ebola vaccine in its own manufacturing facility. These materials will be used for Phase I and early Phase II clinical studies in humans. Crucell will receive up to EUR 21.4 million (US$ 27.6 million) from the VRC for the manufacturing of these clinical lots.